HAS-BLED explained

HAS-BLED score
Purpose:risk of major bleeding

HAS-BLED is a scoring system developed to assess 1-year risk of major bleeding in people taking anticoagulants for atrial fibrillation (AF). It was developed in 2010 with data from 3,978 people in the Euro Heart Survey.[1] Major bleeding is defined as being intracranial bleedings, hospitalization, hemoglobin decrease > 2 g/dL, and/or transfusion.[1]

Definition

HAS-BLED is a medical tool used to calculate the one-year risk of major bleeding for people on blood thinning drugs for atrial fibrillation (AF).[2] It is used with the CHA2DS2-VASc score.[3]

Use

ConditionPoints
 H   Hypertension: (uncontrolled, >160 mmHg systolic)
 A  Abnormal renal function: Dialysis, transplant, Cr >2.26 mg/dL or >200 μmol/LAbnormal liver function

Cirrhosis or Bilirubin >2x Normal or AST/ALT/AP >3x Normal
 S  Stroke: Prior history of stroke
 B  Bleeding: Prior Major Bleeding or Predisposition to Bleeding
 L  Labile INR: (Unstable/high INR), Time in Therapeutic Range < 60%
 E  Elderly: Age > 65 years
 D  Prior Alcohol or Drug Usage History (≥ 8 drinks/week)Medication Usage Predisposing to Bleeding: (Antiplatelet agents, NSAIDs)

A calculated HAS-BLED score is between 0 and 9 and based on seven parameters with a weighted value of 0-2.

The HAS-BLED mnemonic stands for:

A study comparing HEMORR2HAGES, ATRIA and HAS-BLED showed superior performance of the HAS-BLED score compared to the other two.[4] Mixed evidence exist on the comparison between GARFIELD-AF bleeding score over the HAS-BLED.[5] [6]

2020 ESC guidelines on atrial fibrillation recommend assessment of bleeding risk in AF using the HAS-BLED bleeding risk schema as a simple, easy calculation,[7] whereby a score of ≥3 indicates "high risk" and some caution and regular review of the patient is needed.[8] The HAS-BLED score has also been validated in an anticoagulated trial cohort of 7329 people with AF - in this study, the HAS-BLED score offered some improvement in predictive capability for bleeding risk over previously published bleeding risk assessment schemas and was simpler to apply.[9] With the likely availability of new oral anticoagulants that avoid the limitations of warfarin (and may even be safer), more widespread use of oral anticoagulation therapy for stroke prevention in AF is likely.

While their use is recommended in clinical practice guidelines,[10] they are only moderately effective in predicting bleeding risk and don't perform well in predicting hemorrhagic stroke.[11] Bleeding risk may be increased in patients on haemodialysis.[12]

Score

A score of ≥3 indicates "high risk", but does not necessarily mean that an anticoagulant cannot be given, as some risk factors may be modified.[13]

Notes and References

  1. 10.1378/chest.10-0134 . 20299623 . A Novel User-Friendly Score (HAS-BLED) to Assess 1-Year Risk of Major Bleeding in Patients with Atrial Fibrillation . Chest . 138 . 5 . 1093–100 . 2010 . Pisters . Ron . Lane . D. A. . Nieuwlaat . R . De Vos . C. B. . Crijns . H. J. . Lip . G. Y. .
  2. Web site: HAS-BLED Score for Major Bleeding Risk . MDCalc . 11 April 2021 . https://web.archive.org/web/20210225021028/https://www.mdcalc.com/has-bled-score-major-bleeding-risk . 25 February 2021 . en.
  3. Book: Dan. Gheorhe-Andre. https://books.google.com/books?id=PNqUDwAAQBAJ&pg=PA201. The ESC Handbook on Cardiovascular Pharmacotherapy. Steffel. Jan. Oxford University Press. 2019. 978-0-19-875993-5. Kaski. Juan Carlos. Oxford. 201–203. 4.1. Atrial fibrillation. Kjeldsen. Keld Per.
  4. Apostolakis. Stavros. Lane. Deirdre A.. Guo. Yutao. Buller. Harry. Lip. Gregory Y. H.. 28 August 2012. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. Journal of the American College of Cardiology. 60. 9. 861–867. 10.1016/j.jacc.2012.06.019. 1558-3597. 22858389. free.
  5. Fox. Keith A. A.. Lucas. Joseph E.. Pieper. Karen S.. Bassand. Jean-Pierre. Camm. A. John. Fitzmaurice. David A.. Goldhaber. Samuel Z.. Goto. Shinya. Haas. Sylvia. Hacke. Werner. Kayani. Gloria. 21 December 2017. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open. 7. 12. e017157. 10.1136/bmjopen-2017-017157. 2044-6055. 5778339. 29273652.
  6. Proietti. Marco. Rivera-Caravaca. José Miguel. Esteve-Pastor. María Asunción. Romiti. Giulio Francesco. Marin. Francísco. Lip. Gregory Y. H.. 18 September 2018. Predicting Bleeding Events in Anticoagulated Patients With Atrial Fibrillation: A Comparison Between the HAS-BLED and GARFIELD-AF Bleeding Scores. Journal of the American Heart Association. 7. 18. e009766. 10.1161/JAHA.118.009766. 2047-9980. 6222935. 30371183.
  7. Hindricks. Gerhard. Potpara. Tatjana. Dagres. Nikolaos. Arbelo. Elena. Bax. Jeroen J.. Blomström-Lundqvist. Carina. Boriani. Giuseppe. Castella. Manuel. Dan. Gheorghe-Andrei. Dilaveris. Polychronis E.. Fauchier. Laurent. 2020-08-29. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). European Heart Journal. 42. 5. 373–498. 10.1093/eurheartj/ehaa612. 1522-9645. 32860505. free. 1887/3279676. free.
  8. 10.1016/j.amjmed.2010.05.007 . 20887966 . Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation . The American Journal of Medicine . 124 . 2 . 111–4 . 2011 . Lip . Gregory Y.H. .
  9. 10.1016/j.jacc.2010.09.024 . 21111555 . Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation . Journal of the American College of Cardiology . 57 . 2 . 173–80 . 2011 . Lip . Gregory Y.H. . Frison . Lars . Halperin . Jonathan L. . Lane . Deirdre A. .
  10. 10.1093/eurheartj/ehs253 . 22922413 . 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation . European Heart Journal . 33 . 21 . 2719–47 . 2012 . Camm . A. J. . Lip . G. Y. H. . De Caterina . R. . Savelieva . I. . Atar . D. . Hohnloser . S. H. . Hindricks . G. . Kirchhof . P. . Bax . J. J. . Baumgartner . H. . Ceconi . C. . Dean . V. . Deaton . C. . Fagard . R. . Funck-Brentano . C. . Hasdai . D. . Hoes . A. . Kirchhof . P. . Knuuti . J. . Kolh . P. . McDonagh . T. . Moulin . C. . Popescu . B. A. . Reiner . Z. . Sechtem . U. . Sirnes . P. A. . Tendera . M. . Torbicki . A. . Vahanian . A. . Windecker . S. . 29 . free .
  11. 10.1007/s11239-013-0899-7 . 23479259 . 3888359 . Assessing bleeding risk in patients taking anticoagulants . Journal of Thrombosis and Thrombolysis . 35 . 3 . 312–9 . 2013 . Shoeb . Marwa . Fang . Margaret C. .
  12. 10.1053/j.ajkd.2007.06.017 . 17720522 . Warfarin Anticoagulation in Hemodialysis Patients: A Systematic Review of Bleeding Rates . American Journal of Kidney Diseases . 50 . 3 . 433–40 . 2007 . Elliott . Meghan J. . Zimmerman . Deborah . Holden . Rachel M. .
  13. Book: Kiser . Kathryn . Oral Anticoagulation Therapy: Cases and Clinical Correlation . 2017 . Springer . 9783319546438 . 20 . en.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "HAS-BLED".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.